ALK and neuroblastoma: Importantly, PF-06463922 abrogates ALK activity in the single-digit nanomolar range in all our different preclinical assays, including the neuroblastoma hot-spot mutations, ALKF1174, ALKF1245 and ALKR1275 (Bresler et al., 2014; De Brouwer et al., 2010).